

ACURA PHARMACEUTICALS, INC

Form 8-K

October 17, 2011

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D. C. 20549

---

FORM 8-K

CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act Of 1934

October 17, 2011  
Date of Report (Date of earliest event reported)

---

ACURA PHARMACEUTICALS, INC.  
(Exact Name of Registrant as Specified in Charter)

---

State of New York  
(State of Other Jurisdiction  
of Incorporation)

1-10113  
(Commission File Number)

11-0853640  
(I.R.S. Employer  
Identification Number)

616 N. North Court, Suite 120  
Palatine, Illinois 60067  
(Address of principal executive offices) (Zip Code)

(847) 705-7709  
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR 240.13e-4(c))

Item 8.01

Other Events

On October 17, 2011 we issued a press release announcing that Pfizer, Inc. (Pfizer) has unformed us that it has commenced executing its commercialization plan for OXECTA®(oxycodone HCl, USP) Tablets CII in the United States. A copy of our press release is being furnished as Exhibit 99.1 hereto.

Item 9.01

Financial Statements and Exhibits

| Exhibit Number | Description |
|----------------|-------------|
|----------------|-------------|

|      |                                      |
|------|--------------------------------------|
| 99.1 | Press Release dated October 17, 2011 |
|------|--------------------------------------|

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

ACURA PHARMACEUTICALS, INC.

By: /s/ Peter A. Clemens  
Peter A. Clemens  
Senior Vice President & Chief Financial Officer

Date: October 17, 2011

---

Exhibit Index

| Exhibit Number | Description                          |
|----------------|--------------------------------------|
| 99.1           | Press Release dated October 17, 2011 |

---